GlobeNewswire

Galapagos increases share capital through warrant exercise by Gilead

Share

Mechelen, Belgium; 6 November 2019, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from a warrant exercise by Gilead.

On 1 November 2019, Galapagos NV (the "Company" or "Galapagos") announced that Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ: GILD) ("Gilead"), delivered an exercise notice to Galapagos in order to exercise the Initial Warrant A.

Initial Warrant A, approved by Galapagos' shareholders on 22 October 2019, entitles the holder thereof to subscribe for a maximum number of shares that is sufficient to bring the number of shares owned by Gilead and any of its affiliates to 25.1% of the actually issued and outstanding shares immediately after the issue of the shares that are to be issued upon the relevant exercise of Initial Warrant A. Initial Warrant A has a term of one year starting as of 22 October 2019.

As a result of the exercise of the Initial Warrant A, Gilead subscribed for 2,617,791 shares at €140.59 per share for a total of €368,035,236.69. The new shares were issued on 6 November 2019.

In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €349,274,259.52, the total number of securities conferring voting rights is 64,571,622, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe for not yet issued securities conferring voting rights consists of (i) 5,636,297 warrants under several outstanding employee warrant plans, which equals 5,636,297 voting rights that may result from the exercise of those warrants, and (ii) two warrants issued to Gilead Therapeutics to subscribe for a maximum number of shares that is sufficient to bring the shareholding of Gilead and its affiliates to 25.1% and 29.9%, respectively, of the actually issued and outstanding shares after the exercise of the relevant warrant. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contacts

Investors:
Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Director Investor Relations
+32 485 19 14 15
ir@glpg.com

Media:
Carmen Vroonen
Senior Director Communications & Public Affairs
+32 473 824 874

Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com

Forward-looking statements
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These
forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.





1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions.



Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Maha Energy AB (publ) (“Maha” or the “Company”) announce change of time for Question and Answer Session Wednesday 13 November11.11.2019 22:00:00 CETPress release

­­­Maha Energy AB (publ) Strandvägen 5A SE-114 51 Stockholm www.mahaenergy.ca Press release Stockholm November 11, 2019 Maha Energy AB (publ) (“Maha” or the “Company”) announce change of time for Question and Answer Session Wednesday 13 November Earlier today, the Company announced it would be holding a Question and Answer Session on Wednesday 13 November at 4 PM CET. The time has been changed to 5 PM (CET) the same day. The webcast link will be posted on the Company’s website and is as follows: https://www.youtube.com/watch?v=xOs_y_-OS3M&feature=youtu.be Shareholders and investors can pose questions at the time of the live session, or questions can also be sent ahead of time to: victoria@mahaenergy.ca Adviser Certified Advisor: FNCA Sweden AB, info@fnca.se, Telephone: +46-8-528 00 399. For more information, please contact: Jonas Lindvall (CEO) Tel: +1 403 454 7560 Email: jonas@mahaenergy.ca or Ron Panchuk (EVP) Tel: +1 403 454 7560 Email: ron@mahaenergy.ca Miscellaneous The informatio

Valberedning nominerar Jesper Söderqvist till Arcomas styrelse11.11.2019 18:01:00 CETPress release

11 november 2019 PRESSRELEASE Valberedning nominerar Jesper Söderqvist till Arcomas styrelse Valberedningen i Arcoma AB meddelar idag att den avser att nominera Jesper Söderqvist som ordinarie medlem i bolagets styrelse vid Årsmötet 20 maj 2020. Valberedningen återkommer med sitt fullständiga förslag i samband med kallelse till Årsmötet. För ytterligare information var god kontakta: Lars Kvarnhem, styrelsens ordförande Telefon: 070-512 00 21 E-mail: lars.kvarnhem@priego.se Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 11 november 2019, kl. 18:00 För mer information om Arcoma, besök www.arcoma.se Attachment 191111 Pressrelease Valberedning nominerar Jesper Söderqvist

Jesper Söderqvist lämnar sin VD-post andra kvartalet 2020 och tar plats i Arcomas styrelse11.11.2019 18:00:00 CETPress release

11 november 2019 PRESSRELEASE Jesper Söderqvist lämnar sin VD-post andra kvartalet 2020 och tar plats i Arcomas styrelse Jesper Söderqvist har meddelat styrelsen att han kommer lämna sin VD-post under andra kvartalet 2020. Samtidigt har valberedningen idag också meddelat att den avser nominera Jesper Söderqvist till Arcomas styrelse vid Årsmötet 2020. Jesper Söderqvist har enligt sitt anställningsavtal sex månaders uppsägningstid och kommer att fortsätta i sin nuvarande roll tillsvidare, han lämnar VD-posten i Arcoma under andra kvartalet 2020. Styrelsen kommer nu att påbörja rekrytering av en efterträdare. ”Jesper har hjälpt oss att förstärka Arcoma ytterligare. Han har byggt vidare på vår grund för fortsatt positiv utveckling. Tillsammans med vårt Management Team har han arbetat intensivt och framgångsrikt med fokusering på starka strategiska samarbeten och ett tydligt fokus på operativa förbättringar. Detta har lett till att Arcoma idag står väl rustat för en fortsatt positiv försäl

Arion Bank: Transactions in relation to a share buyback programme11.11.2019 16:41:00 CETPress release

In week 45 Arion Bank purchased own shares on Nasdaq Iceland and Swedish Depository Receipts (SDR) on Nasdaq Stockholm. See further details below. Share buyback on Nasdaq Iceland Week Date Time Number of shares Share price Purchase price (ISK) Number of shares owned by Arion bank after trade 45 04/11/2019 10:14 500,000 79.5 39,750,000 1,299,899 45 04/11/2019 14:04 300,000 79.3 23,790,000 1,599,899 45 05/11/2019 09:51 850,000 80.1 68,085,000 2,449,899 45 06/11/2019 09:49 600,000 78.5 47,100,000 3,049,899 45 06/11/2019 13:46 300,000 78.8 23,640,000 3,349,899 45 07/11/2019 09:39 550,000 79.3 43,615,000 3,899,899 45 07/11/2019 09:39 5,000 79.3 396,500 3,904,899 45 07/11/2019 09:57 300,000 79.3 23,790,000 4,204,899 45 08/11/2019 10:15 558,000 79.3 44,249,400 4,762,899 45 08/11/2019 10:16 300,000 79.3 23,790,000 5,062,899 45 08/11/2019 10:23 60,000 79.3 4,758,000 5,122,899 Week 45 Total 4,323,000 342,963,900 Buyback of SDR’s on Nasdaq Stockholm Week Date Time Number of SDR's Price per SDR Pu

Awilco Drilling PLC: Primary Insider Disclosure11.11.2019 16:22:00 CETPress release

Awilco Drilling PLC (AWDR) announces that on 11th November 2019, the following synthetic share transactions occurred: Roddy Smith has had 55,395 synthetic shares vested in AWDR automatically exercised under the Synthetic Share Plan at a price of NOK 17.87. After this transaction and as of today, Roddy Smith, holds 133,517 synthetic shares. Ian Wilson has had 55,395 synthetic shares vested in AWDR automatically exercised under the Synthetic Share Plan at a price of NOK 17.87. After this transaction and as of today, Ian Wilson holds 115,454 synthetic shares. Claus Mørch has had 49,399 synthetic shares vested in AWDR automatically exercised under the Synthetic Share Plan at a price of at NOK 17.87. After this transaction and as of today, Claus Mørch holds no further synthetic shares. Aberdeen, 11 November 2019 For further information please contact: Jens Berge, CEO Phone: +44 1224 737900 Cathrine Haavind, IR Manager Phone: +47 9342 8464 Email: ch@awilcodrilling.com This information is sub

Awilco Drilling PLC: Minutes of Meeting from General Meeting11.11.2019 13:31:00 CETPress release

A General Meeting of Awilco Drilling PLC (Ticker: AWDR) was held Monday 11 November 2019 at 12:00 p.m. (UK time), at the Company’s offices, 2 Kingshill Park, Venture Drive, Arnhall Business Park, Westhill, Aberdeen AB32 6FL, UK. Each of the resolutions set out in the Meeting Notice were duly passed. The signed minutes of meeting are attached hereto. The Meeting Notice and Appendices are available on our website www.awilcodrilling.com, under ‘Investor Relations/General Meetings’. Aberdeen, 11 November 2019 For further information please contact: Jens Berge, CEO Phone: +44 1224 737900 Cathrine Haavind, IR Manager Phone: +47 93 42 84 64 Email: ch@awilcodrilling.com This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment AWDR GM Meeting Minutes 11 November 2019